Premonitory-like Symptomatology in Migraine

Nazia Karsan1 and Peter J Goadsby2

1. Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 2. NIHR and Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK

DOI: https://doi.org/10.17925/ENR.2017.12.01.28

It has been historically accepted that migraine involves symptomatology outside of head pain. These symptoms can be as equally disabling as the pain, and can include tiredness, concentration impairment, memory impairment and mood change. The symptoms may start before the onset of pain and can persist throughout the headache phase, and even after effective headache treatment into the postdrome. Despite knowledge of these symptoms, their neurobiologic basis and relationship to migraine pain is poorly understood. The fact that these symptoms start early, up to hours to days before the onset of headache, and are so symptomatically heterogeneous, suggests that the neurobiology of migraine extends beyond conventionally accepted anatomical pain areas within the brain – what has been known as the pain matrix or network. In a research area where no effective acute abortive drugs have gained a license for migraine since the 1990s, further understanding of such symptomatology will allow therapeutic advances for treatments that may work before the onset of migraine pain and thus prevent it. This review will outline our current understanding about the phenotype and neurobiology of the premonitory (prodromal) symptoms, which for the purpose of this review will be called ‘premonitory-like’, given they can start before or during pain. Symptoms starting after pain resolution (postdromal symptoms) will not be covered here.

Keywords
Migraine, premonitory, prodrome, functional imaging

Disclosure: Nazia Karsan is an Association of British Neurologists GUARDIANs of Brain Clinical Research Training Fellow. Peter J Goadsby reports personal fees from Allergan, Amgen, and Eli-Lilly and Company; and personal fees from Akida Biomedical, Alder Biopharmaceuticals, Autonomic Technologies Inc., A瓦ini Pharma, Cipla Ltd, ColUcid Pharmaceuticals Inc., Dr Reddy’s Laboratories, eNetra, ElectroCore LLC, Navarins, Pfizer Inc., Promius Pharma, Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc., Scion; and personal fees from MedicoLegal work, Journal Watch, Up-to-Date, Oxford University Press; in addition, Peter J Goadsby has a magnet stimulation for headache patent pending assigned to eNetra. No funding was received for the publication of this article. Peter J Goadsby is a member of the European Neurological Review Editorial Board.

Compliance with Ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.

Open Access: This article is published under the Creative Commons Attribution NonCommercial License, which permits any non-commercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.

Received: 12 March 2017
Accepted: 25 April 2017
Citation: European Neurological Review, 2017;12(1):28–30
Corresponding Author: Peter J Goadsby, Wellcome Foundation Building, King’s College Hospital, London, UK. E: peter.goadsby@kcl.ac.uk

It has been recognised for centuries that symptoms outside of pain are reported with migraine.1 Symptoms prior to the onset of migraine headache have been called premonitory or prodromal symptoms and the symptoms after headache resolution have been called postdromal or resolution symptoms in the literature.2,3 These symptoms are likely to be a continuum, starting before the onset of headache, and persisting throughout the headache phase, perhaps becoming less noticeable in the presence of moderate-to-severe pain. They can also persist after the resolution of pain before return to normal function, and studies have shown similarities in the phenotype of premonitory and postdromal symptoms.4

These non-painful cognitive, homeostatic and sensory sensitivity symptoms can be disabling and prevent normal function, adding to the morbidity associated with a migraine attack. It is therefore important to recognize their phenotype and relationship to headache, and further to understand their neurobiology. Most research in this field has focused on symptoms displayed before the onset of moderate-severe migraine headache. However, for the purpose of this review we call the symptoms ‘premonitory-like’ as we have observed that they can start at the same time as pain, or occur during the pain itself. Whether symptoms start before or during pain, they are likely to be biologically mediated in the same way, regardless of their onset within the migraine timeline; hence the use of this definition here. For the purpose of this review, premonitory-like symptoms will be defined as any non-painful symptom associated with the migraine attack, possibly predictive of impending headache and starting before the onset of pain, or non-migraine-defining symptoms occurring during the pain itself. Postdrome or resolution symptoms are neurobiologically poorly understood at the moment, and phenotypically not well reported in the literature and will therefore not be included in this review.

It should also be noted that premonitory-like symptoms are often mistaken as migraine triggers; for example, a craving for chocolate may be a premonitory symptom, but patients are likely to interpret this as chocolate often triggering a migraine headache in them.4 Increasingly, the evidence suggests that many of the triggers reported by patients are not reproducible in experimental research, and may actually represent the manifestation of premonitory-like symptomatology.5,6 Therefore, there is an increasing need to understand the mediation of such symptoms, and their differentiation from migraine triggers, to allow patients to understand their condition better and effectively manage their lifestyles accordingly.

Prevalence of premonitory-like symptoms in migraine

The true prevalence of premonitory symptoms among migraineurs is unknown, as most of the studies are retrospective and the numbers reported vary greatly across different studies.4,7–9 In addition, the majority of the studies performed so far have only looked at symptoms starting before the...
onset of headache, the true definition of ‘premonitory symptoms’, rather than looking at the development of such symptoms with or during the onset of pain. Various retrospective studies in the literature have quoted prevalence rates of 9–88%.3,8–16 See Table 1 for a breakdown of studies to date in the literature looking at premonitory symptom prevalence.

Regardless of the prevalence, Giffin et al.16 showed with an electronic diary study that the experience of these symptoms is highly predictive of impending migraine headache. In this study patients were reliably able to predict the onset of headache 72% of the time, after reporting of impending migraine headache. In this study patients were reliably interviewed, self-administered questionnaires or electronic diaries, and whether data were collected from the headache clinic or wider population, the phenotype of symptoms reported in adults is largely consistent across these studies (see Table 1).1,16 The most common symptoms seem to be fatigue (see red in Table 1), mood change (see blue in Table 1) and yawning (see green in Table 1). These are consistent across the studies. Other common symptoms are neck stiffness and concentration difficulty.

The most commonly reported symptoms group largely into cognitive- or sleep-related symptoms (mood change, concentration or memory impairment, yawning, sleep disturbance and fatigue), migraine-like symptoms and sensory sensitivities (photophobia, phonophobia, nausea, mild head or eye discomfort and neck stiffness) and other homeostatic symptoms such as frequency of micturition, food cravings and bowel habit change. Paediatric studies have shown that the phenotype in children and adolescents is mostly comparable to that in adults.17,18

### Relationship of symptoms to the neurobiology of migraine

The role of the brainstem as the driver for migraine attacks has been increasingly accepted.19 Various imaging studies in humans have now shown activity in brainstem structures during acute pain.20,24 Premonitory-like symptomatology clearly involves brain areas outside of pain pathways, given the variable phenotype of symptoms produced. The broad groups of symptoms that most of the symptoms reported by patients fall into could help us understand the biologic basis of the symptoms, by considering involvement of the limbic system (emotional change, tiredness and concentration impairment),25 dopaminergic pathways (yawning),26 the hypothalamus (neck discomfort, sleep disturbance, thirst, cravings, frequency of micturition)27,28 and other brainstem areas (nucleus of tractus solitarius and nausea).29

### Phenotype of premonitory-like symptoms

Despite the varying population types used in the studies performed to date, as well as varying methods of data collection, such as patient interview, self-administered questionnaires or electronic diaries, and

---

**Table 1: A summary of studies performed looking into premonitory symptomatology in migraine**

<table>
<thead>
<tr>
<th>Study</th>
<th>Design and recruitment</th>
<th>n</th>
<th>Patients selected</th>
<th>Most common premonitory symptoms reported</th>
<th>Prevalence if available (of at least one or more symptom)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blau (1980)</td>
<td>Retrospective oral questioning (clinic)</td>
<td>50</td>
<td>Adults and children (minimum age 12)</td>
<td>Tiredness, tiredness, mood change</td>
<td>34%</td>
</tr>
<tr>
<td>Drummond and Lance (1984)</td>
<td>Retrospective oral questioning (clinic)</td>
<td>530</td>
<td>Adults</td>
<td>Mood change, appetite change, changes in alertness</td>
<td>30%</td>
</tr>
<tr>
<td>Amery et al. (1986)</td>
<td>Retrospective questionnaire (population)</td>
<td>149</td>
<td>Adults</td>
<td>Low energy, pallor, photophobia, phonophobia</td>
<td>Presellected as having premonitory symptoms</td>
</tr>
<tr>
<td>Waaalens (1985)</td>
<td>Prospective questionnaire (clinic)</td>
<td>49</td>
<td>Adults</td>
<td>Irritability, depression, fatigue, hunger, bulimia, yawning</td>
<td>88%</td>
</tr>
<tr>
<td>Russell et al. (1996)</td>
<td>Retrospective face-to-face/telephone interview (clinic)</td>
<td>484</td>
<td>Adults</td>
<td>Hyperactivity, depression, fatigue, hunger</td>
<td>9%</td>
</tr>
<tr>
<td>Rasmussen et al. (1992)</td>
<td>Retrospective interview and questionnaire (population)</td>
<td>1,000</td>
<td>Adults</td>
<td>Depression, tiredness, hyperactivity</td>
<td>14%</td>
</tr>
<tr>
<td>Kelman (2004)</td>
<td>Retrospective interview (clinic)</td>
<td>893</td>
<td>Adults</td>
<td>Tiredness, malaise, fatigue, mood change</td>
<td>30%</td>
</tr>
<tr>
<td>Griffin et al. (2003)</td>
<td>Prospective, electronic diary (clinic)</td>
<td>97</td>
<td>Adults</td>
<td>Tiredness, concentration difficulty, stiff neck</td>
<td>Presellected as having premonitory symptoms</td>
</tr>
<tr>
<td>Schoonman et al. (2006)</td>
<td>Retrospective questionnaire (clinic)</td>
<td>461</td>
<td>Adults</td>
<td>Fatigue, phonophobia, yawning</td>
<td>87%</td>
</tr>
<tr>
<td>Quintela et al. (2006)</td>
<td>Retrospective questionnaire (GP surgery)</td>
<td>100</td>
<td>Adults</td>
<td>Anxiety, phonophobia, irritability, low mood, yawning</td>
<td>84%</td>
</tr>
<tr>
<td>Cuveller et al. (2009)</td>
<td>Retrospective questionnaire (clinic)</td>
<td>103</td>
<td>Children and adolescents</td>
<td>Face change, fatigue, irritability</td>
<td>67%</td>
</tr>
<tr>
<td>Karsan et al. (2016)</td>
<td>Retrospective, analysis of clinic letters (clinic)</td>
<td>100</td>
<td>Children and adolescents</td>
<td>Fatigue, mood change, neck stiffness, yawning</td>
<td>Presellected as having premonitory symptoms</td>
</tr>
</tbody>
</table>

The most common premonitory symptoms are colour-coded: fatigue (red), mood change (blue) and yawning (green).
The occurrence of premonitory symptoms, their ability to predict an impending headache and the anatomical structures alluded to in imaging studies during premonitory symptoms, suggest that they could provide vital neurobiologic information about the basis of a migraine attack, and important clues about therapeutic development in the future. If we can understand the neurotransmitter systems at play early before the onset of pain, we may be able to understand how to develop targeted therapies that work on these systems and may be able to prevent pain onset at all. Small studies of this type have been performed using domperidone, taken during premonitory symptoms, acting on the dopamine pathway, and have shown promising results, but larger randomised placebo-controlled trials are warranted.

In addition, trigger studies as a way of modelling human migraine have also increased knowledge in this area. Nitroglycerin (NTG) and pituitary adenylylate-cyclase activating protein (PACAP) have been shown to be able to trigger premonitory symptoms in migraineurs, similar to those experienced with spontaneous attacks. NTG is a well-established migraine-triggering model in the literature, but it has been used extensively yet to study premonitory-like symptomatology. PACAP is newer in migraine research and its ability to trigger migraine has led to interest in agents targeted against the PAC1 receptor as a possible treatment for migraine. In a similar way, the human triggering models may, in the future, allow us to explore newer effective triggering compounds and thereby further study antagonising the exogenous trigger molecules, in the hope of being able to prevent premonitory symptom and pain onset.

Conclusions
Migraine is a disorder of more than head pain, and comprises heterogeneous non-painful symptomatology that can be equally debilitating, and contribute to the morbidity of the attack. These non-painful symptoms may start hours to days before the onset of pain, or start alongside the pain, and may persist after headache resolution. It is likely from observation of our patients in the clinic that these symptoms are probably under-reported. This is partly due to failure of patient recognition unless asked, and due to physicians not asking about specific symptoms that patients may not themselves have associated with a headache attack, or may have associated with trigger factors rather than premonitory-like symptoms. Recognition of the presence of these symptoms, particularly before the onset of headache, and differentiation of them from true migraine triggers, can help patients understand the wider impact of the attack, and reliably predict the onset of impending headache, as well as allow early and effective headache management. Education about these symptoms, and helping patients understand that these are explained as being part of the migraine attack, can increase understanding of the symptoms, and limit unnecessary misinterpretation of some of these symptoms as migraine triggers and therefore limit unhelpful lifestyle modifications. In addition, in the paediatric population, education about the recognition of these symptoms among parents, teachers and carers, can allow prompt treatment in this population who may not always be able to display or vocalise pain. From a research perspective further understanding of the neurobiologic basis of these symptoms, through functional imaging and through pre-clinical models, will help us understand the regions of the brain likely to be involved, and thereby help with planning future therapeutic clinical trials.

In addition, increasingly studying the symptoms in humans through triggering models, imaging studies and treatment in randomised-controlled trials may help us identify future therapeutic targets. Identification of specific neurotransmitter systems in certain brain regions could help development of targeted migraine therapies, in an exciting era when migraine therapeutics has evolved greatly, but there will always be a need for more targeted acute and preventative therapies to help those affected by this disabling disorder with greater efficacy and limited side-effect profiles. Future clinical trials should assess efficacy of the drugs in question in treating associated non-headache symptomatology in migraine, as well as headache, as this can be equally debilitating and impair the quality of life of those affected.